Novo Nordisk's CEO tells Scrip why the Danish group's R&D approach must embrace risk earlier to ensure "differentiated" products in an increasingly competitive world.
Novo Nordisk AS CEO Lars Fruergaard Jorgensen believes the Danish company under his leadership and management team during his first year in the role "met expectations in 2017" after a less-than-stellar 2016, and is well on its way to revamping its R&D approach.
The Dane in an interview with Scrip also said he remained on the look-out for an acquisition in the rare...
The French company will start shipping its blockbuster shortly to meet expected strong demand in the 2025–26 RSV season.
Otsuka bested Vera on Phase III immunoglobulin A nephropathy data for proteinuria, but analysts wonder if the difference is especially meaningful.
The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.
EFPIA says reforms make the continent less attractive for innovative firms.
The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.
Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.
Public Company Edition: Public company funding in 2025 is down from 2024, but after recent positive data readouts Vera accessed up to $450m in new debt, while Taysha and Trevi grossed $200m and $100m, respectively, in stock offerings. Meanwhile, Keros, Stealth and others cut jobs.
